Larogen100 (Larotrectinib )100mg
£0.00
Larogen capsules hold 100mg of Larotrectinib, a targeted therapy employed in oncology to treat solid tumors possessing neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Acting as a tyrosine kinase inhibitor, Larotrectinib blocks particular enzymes engaged in the growth and multiplication of cancer cells. Healthcare providers prescribe Larogen capsules as a component of the treatment plan for suitable patients diagnosed with these precise tumor types.
Indication:
Larogen capsules, each containing 100mg of Larotrectinib, are prescribed for treating solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusions.
Pharmacology:
Larotrectinib, the active component in Larogen capsules, acts as a tyrosine kinase inhibitor. It selectively blocks specific enzymes crucial for tumor growth and proliferation, particularly those linked to NTRK gene fusions. This inhibition helps to halt tumor progression.
Dosage and Administration:
Typically, Larogen capsules are orally administered once daily. The precise dosage depends on individual patient factors like weight, overall health, and the type and severity of the cancer being treated. Patients should strictly adhere to the dosage instructions provided by their healthcare provider.
Interaction:
Larotrectinib might interact with various medications, including other tyrosine kinase inhibitors and drugs metabolized by cytochrome P450 enzymes. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to prevent potential interactions.
Side Effects:
Common side effects of Larogen capsules may encompass fatigue, nausea, vomiting, diarrhea, dizziness, and alterations in taste. More severe reactions like hepatotoxicity, cardiac toxicity, and allergic responses are also possible. Patients should promptly inform their healthcare provider about any severe or persistent side effects.
Precautions and Warnings:
Patients on Larogen capsules should undergo close monitoring for potential adverse reactions, including liver function tests and cardiac monitoring. Use of Larotrectinib during pregnancy may lead to fetal harm, necessitating contraception for both males and females during treatment and for a specified period afterward. Breastfeeding is not recommended while taking Larogen capsules.
Overdose Effects:
In the event of Larogen capsule overdose, patients may experience intensified adverse effects such as nausea, vomiting, diarrhea, and dizziness. Management typically involves supportive care and monitoring for complications. Immediate medical attention is recommended if overdose is suspected.
Product Name | Larogen100 |
---|---|
Generic Name | Larotrectinib |
Formulation | Capsule |
Available Pack Size | 30's |
Available Strength | 100mg |
You must be logged in to post a review.
Reviews
There are no reviews yet.